Tom 16, Nr 4 (2021)
Artykuł przeglądowy
Opublikowany online: 2021-05-07
Wyświetlenia strony
389
Wyświetlenia/pobrania artykułu
823
Migotanie przedsionków i niewydolność serca z zachowaną frakcją wyrzutową
DOI: 10.5603/FC.a2021.0021
Folia Cardiologica 2021;16(4):275-280.
Streszczenie
Niewydolność serca z zachowaną frakcją wyrzutową (HFpEF) i migotanie przedsionków (AF) to jednostki chorobowe wciąż stanowiące wyzwanie we współczesnej kardiologii. Szacuje się, że ponad połowę przypadków niewydolności serca stanowi HFpEF, zaś AF jest częstą chorobą współistniejącą w tej grupie, która może maskować rozpoznanie i przebieg HFpEF oraz pogarszać rokowanie. W niniejsztm artykule przedstawiono aktualny stan wiedzy dotyczącej HFpEF oraz znaczenia AF w tej grupie chorych.
Słowa kluczowe: niewydolność serca z zachowaną frakcją wyrzutowąmigotanie przedsionkówAFHFpEF
Referencje
- Pieske B, Tschöpe C, de Boer RA, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail. 2020; 22(3): 391–412.
- Hindricks G, Potpara T, Dagres N, et al. ESC Scientific Document Group . 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021; 42(5): 373–498.
- Santhanakrishnan R, Wang Na, Larson MG, et al. Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction. Circulation. 2016; 133(5): 484–492.
- Sartipy U, Dahlström U, Fu M, et al. Atrial fibrillation in heart failure with preserved, mid-range, and reduced ejection fraction. JACC Heart Fail. 2017; 5(8): 565–574.
- Zafrir B, Lund LH, Laroche C, et al. ESC-HFA HF Long-Term Registry Investigators. Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14 964 patients in the European Society of Cardiology Heart Failure Long-Term Registry. Eur Heart J. 2018; 39(48): 4277–4284.
- Olsson LG, Swedberg K, Ducharme A, et al. CHARM Investigators. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol. 2006; 47(10): 1997–2004.
- Pfeffer MA, Claggett B, Assmann SF, et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. Circulation. 2015; 131(1): 34–42.
- Lam CSP, Rienstra M, Tay WT, et al. Atrial fibrillation in heart failure with preserved ejection fraction: association with exercise capacity, left ventricular filling pressures, natriuretic peptides, and left atrial volume. JACC Heart Fail. 2017; 5(2): 92–98.
- Mamas MA, Caldwell JC, Chacko S, et al. A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure. Eur J Heart Fail. 2009; 11(7): 676–683.
- Cheng M, Lu X, Huang J, et al. The prognostic significance of atrial fibrillation in heart failure with a preserved and reduced left ventricular function: insights from a meta-analysis. Eur J Heart Fail. 2014; 16(12): 1317–1322.
- McManus DD, Hsu G, Sung SH, et al. Cardiovascular Research Network PRESERVE Study. Atrial fibrillation and outcomes in heart failure with preserved versus reduced left ventricular ejection fraction. J Am Heart Assoc. 2013; 2(1): e005694.
- Schönbauer R, Duca F, Kammerlander AA, et al. Persistent atrial fibrillation in heart failure with preserved ejection fraction: Prognostic relevance and association with clinical, imaging and invasive haemodynamic parameters. Eur J Clin Invest. 2020; 50(2): e13184.
- Kelly JP, DeVore AD, Wu J, et al. Rhythm control versus rate control in patients with atrial fibrillation and heart failure with preserved ejection fraction: insights from get with the guidelines-heart failure. J Am Heart Assoc. 2019; 8(24): e011560.
- Kotecha D, Chudasama R, Lane DA, et al. Atrial fibrillation and heart failure due to reduced versus preserved ejection fraction: A systematic review and meta-analysis of death and adverse outcomes. Int J Cardiol. 2016; 203: 660–666.
- Son MiK, Park JJ, Lim NK, et al. Impact of atrial fibrillation in patients with heart failure and reduced, mid-range or preserved ejection fraction. Heart. 2020; 106(15): 1160–1168.
- Banerjee A, Taillandier S, Olesen JB, et al. Ejection fraction and outcomes in patients with atrial fibrillation and heart failure: the Loire Valley Atrial Fibrillation Project. Eur J Heart Fail. 2012; 14(3): 295–301.
- Sartipy U, Savarese G, Dahlström U, et al. Association of heart rate with mortality in sinus rhythm and atrial fibrillation in heart failure with preserved ejection fraction. Eur J Heart Fail. 2019; 21(4): 471–479.
- Fukui A, Tanino T, Yamaguchi T, et al. Catheter ablation of atrial fibrillation reduces heart failure rehospitalization in patients with heart failure with preserved ejection fraction. J Cardiovasc Electrophysiol. 2020; 31(3): 682–688.
